These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 25966424)
41. [Gallbladder and bile duct carcinoma. Biology and pathology]. Tannapfel A; Wittekind C Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242 [TBL] [Abstract][Full Text] [Related]
42. Tubulocystic Carcinoma of Bile Ducts: A Distinct Type of Cholangiocarcinoma Associated With Adenofibroma-type Lesions. Masetto F; Mafficini A; Saka B; Armutlu A; Chatterjee D; Jang KT; Zen Y; Navale P; Fassan M; Bacchi CE; Mattiolo P; Simbolo M; Ruzzenente A; Lawlor RT; Reid M; Basturk O; Adsay V; Scarpa A; Luchini C Am J Surg Pathol; 2024 Sep; 48(9):1082-1092. PubMed ID: 38946053 [TBL] [Abstract][Full Text] [Related]
43. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Chong DQ; Zhu AX Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149 [TBL] [Abstract][Full Text] [Related]
49. Genetic and epigenetic abnormalities in primary sclerosing cholangitis-associated cholangiocarcinoma. Timmer MR; Beuers U; Fockens P; Ponsioen CY; Rauws EA; Wang KK; Krishnadath KK Inflamm Bowel Dis; 2013 Jul; 19(8):1789-97. PubMed ID: 23615529 [TBL] [Abstract][Full Text] [Related]
50. Molecular profiling reveals potential targets in cholangiocarcinoma. Liu D; Shi Y; Chen H; Nisar MA; Jabara N; Langwinski N; Mattson S; Nagaoka K; Bai X; Lu S; Huang CK World J Gastroenterol; 2023 Jul; 29(25):4053-4071. PubMed ID: 37476584 [TBL] [Abstract][Full Text] [Related]
51. Molecular mechanisms of cholangiocarcinogenesis: are biliary intraepithelial neoplasia and intraductal papillary neoplasms of the bile duct precursors to cholangiocarcinoma? Bickenbach K; Galka E; Roggin KK Surg Oncol Clin N Am; 2009 Apr; 18(2):215-24, vii. PubMed ID: 19306808 [TBL] [Abstract][Full Text] [Related]
52. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228 [TBL] [Abstract][Full Text] [Related]
53. Histological type of intrahepatic cholangiocarcinoma differentiated by genetic alteration from AP-PCR fingerprint. Chuensumran U; Saelee P; Wongkham S; Pairojkul C; Chauin S; Petmitr S Asian Pac J Cancer Prev; 2011; 12(6):1377-80. PubMed ID: 22126467 [TBL] [Abstract][Full Text] [Related]
54. Expression of oxysterol binding protein isoforms in opisthorchiasis-associated cholangiocarcinoma: a potential molecular marker for tumor metastasis. Loilome W; Wechagama P; Namwat N; Jusakul A; Sripa B; Miwa M; Kuver R; Yongvanit P Parasitol Int; 2012 Mar; 61(1):136-9. PubMed ID: 21763455 [TBL] [Abstract][Full Text] [Related]
55. Mutational landscape of intrahepatic cholangiocarcinoma. Zou S; Li J; Zhou H; Frech C; Jiang X; Chu JS; Zhao X; Li Y; Li Q; Wang H; Hu J; Kong G; Wu M; Ding C; Chen N; Hu H Nat Commun; 2014 Dec; 5():5696. PubMed ID: 25526346 [TBL] [Abstract][Full Text] [Related]
56. The interplay of signaling pathways with miRNAs in cholangiocarcinoma pathogenicity and targeted therapy. Zaki MB; Abulsoud AI; Elshaer SS; Fathi D; Abdelmaksoud NM; El-Mahdy HA; Ismail A; Elsakka EGE; Sallam AM; Doghish AS Pathol Res Pract; 2023 May; 245():154437. PubMed ID: 37030167 [TBL] [Abstract][Full Text] [Related]